CAS 184475-35-2

Gefitinib

Description:

Gefitinib is a small molecule tyrosine kinase inhibitor primarily used in the treatment of non-small cell lung cancer (NSCLC) that harbors specific mutations in the epidermal growth factor receptor (EGFR). Its chemical formula is C22H24ClFN4O3, and it features a complex structure that includes a quinazoline core. Gefitinib works by selectively inhibiting the tyrosine kinase activity of the EGFR, thereby blocking downstream signaling pathways that promote cell proliferation and survival. This mechanism of action makes it particularly effective in tumors with activating mutations in the EGFR gene. Gefitinib is administered orally and is characterized by its moderate solubility in water and its ability to penetrate biological membranes, which is crucial for its therapeutic efficacy. Common side effects associated with gefitinib include skin rash, diarrhea, and liver enzyme elevations. Its pharmacokinetics are influenced by factors such as food intake and liver function, necessitating careful monitoring during treatment. Overall, gefitinib represents a targeted therapy that has significantly improved outcomes for patients with specific types of lung cancer.

Formula: C₂₂H₂₄ClFN₄O₃

InChI: InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)

InChI key: InChIKey=XGALLCVXEZPNRQ-UHFFFAOYSA-N

SMILES: N(C=1C2=C(C=C(OC)C(OCCCN3CCOCC3)=C2)N=CN1)C4=CC(Cl)=C(F)C=C4

Synonyms:

• (3-Chloro-4-fluorophenyl)[7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-yl]amine
• 4-(3-Chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxy]quinazoline
• 4-(3′-Chloro-4′-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
• 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-
• Akos 91371
• Gefitinib
• Gefitinib Base
• Gefitinib(TINIBS)
• Gefitinib, Iressa, ZD1839
• Gefonib
• Geftinib
• N-(3-Chloro-4-Fluoro-Phenyl)-7-Methoxy-6-(3-Morpholin-4-Ylpropoxy)Quinazolin-4-Amine
• N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
• N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine
• Zd 1839
• Zd1839

Gefitinib

CAS: 184475-35-2

Formula: C₂₂H₂₄ClFN₄O₃

Purity: >98.0%(T)(HPLC)

Color and Shape: White to Light yellow powder to crystal

Molecular weight: 446.91

Ref: 3B-G0546

GEFITINIB CRS

CAS: 184475-35-2

GEFITINIB CRS

Ref: 41-Y0001813

GEFITINIB FOR SYSTEM SUITABILITY CRS

CAS: 184475-35-2

GEFITINIB FOR SYSTEM SUITABILITY CRS

Formula: C₂₂H₂₄ClFN₄O₃

Molecular weight: 446.9024

Ref: 41-Y0001809

Gefitinib

CAS: 184475-35-2

Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds, nesoi

Formula: C₂₂H₂₄ClFN₄O₃

Color and Shape: White Powder

Molecular weight: 446.1521

Ref: 45-1289105

N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine

CAS: 184475-35-2

Formula: C₂₂H₂₄ClFN₄O₃

Purity: 98%

Color and Shape: Solid

Molecular weight: 446.9024

Ref: IN-DA0039KY

Gefitinib

CAS: 184475-35-2

Gefitinib

Formula: C₂₂H₂₄ClFN₄O₃

Purity: ≥98%

Molecular weight: 446.9

Ref: 54-BUP17082

Gefitinib

CAS: 184475-35-2

Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations.

Formula: C₂₂H₂₄ClFN₄O₃

Purity: 99.92% - >99.99%

Color and Shape: Light-Yellow Crystalline Powder

Molecular weight: 446.90

Ref: TM-T1181

Gefitinib

CAS: 184475-35-2

Gefitinib

Formula: C₂₂H₂₄ClFN₄O₃

Color and Shape: White Solid

Molecular weight: 446.90236

Ref: 54-BISN0101

Gefitinib

CAS: 184475-35-2

Formula: C₂₂H₂₄ClFN₄O₃

Color and Shape: White To Off-White Solid

Molecular weight: 446.91

Ref: 4Z-G-231

Gefitinib

CAS: 184475-35-2

Formula: C₂₂H₂₄ClFN₄O₃

Purity: ≥ 99.0%

Color and Shape: White to off-white powder

Molecular weight: 446.90

Ref: 7W-GP9843

Gefitinib

Controlled Product

CAS: 184475-35-2

Formula: C₂₂H₂₄ClFN₄O₃

Color and Shape: White Solid

Molecular weight: 446.90

Ref: 86-MM3563.00

Gefitinib

CAS: 184475-35-2

Formula: C₂₂H₂₄ClFN₄O₃

Molecular weight: 446.91

Ref: ST-EA-CP-G14000

Gefitinib

Controlled Product

CAS: 184475-35-2

Formula: C₂₂H₂₄ClFN₄O₃

Color and Shape: Neat

Molecular weight: 446.9

Ref: TR-G304000

Gefitinib

CAS: 184475-35-2

RIPK2 protein kinase inhibitor; EGFR inhibitor

Formula: C₂₂H₂₄ClFN₄O₃

Purity: Min. 98 Area-%

Color and Shape: Powder

Molecular weight: 446.9 g/mol

Ref: 3D-FG10816

Gefitinib - Bio-X ™

CAS: 184475-35-2

Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) protein. This inhibition is on the EGFR tyrosine kinase domain, where Gefitinib bindings to the ATP-binding site. As a a tyrosine kinase inhibitor, Gefitinib blocks tumor growth and has led to its use in slowing the progression of non-small cell lung cancer. Gefitinib also inhibits invasion and metastasis through inhibition of macrophage receptor interacting protein kinase 2 (RIPK2), rather than EGFR.

Formula: C₂₂H₂₄ClFN₄O₃

Purity: Min. 98 Area-%

Color and Shape: Powder

Molecular weight: 446.9 g/mol

Ref: 3D-BG164498

N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine

CAS: 184475-35-2

Formula: C₂₂H₂₄ClFN₄O₃

Purity: 98%

Color and Shape: Solid, Light yellow crystalline powder

Molecular weight: 446.91

Ref: 10-F079438

Gefitinib-d6

Controlled Product

CAS: 184475-35-2

Applications Gefitinib-d6 is the labeled version of Gefitinib (G304000), which is an antineoplastic.
References Anderson, N.G., et al.: Int. J. Cancer, 94, 774 (2001), Hirata, A., et al.: Cancer Res., 62, 2554 (2002), Kris, M.G., et al.: J. Am. Med. Assoc., 290, 2149 (2003), Tamura, K., et al.: Expert Opin. Pharmacother., 6, 985 (2005)

Formula: C₂₂D₆H₁₈ClFN₄O₃

Color and Shape: Neat

Molecular weight: 452.939

Ref: TR-G304008

Gefitinib RS

CAS: 184475-35-2

Color and Shape: White Solid Powder

Ref: 2K-1055700021